Paraneoplastic Cushing syndrome, case-series and review of the literature

References

• Lacroix A, Feelders RA, Stratakis CA, et al. Cushing’s syndrome. Lancet. 2015;386(9996):913–927.10.1016/S0140-6736(14)61375-1
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010;11(2):117–126.10.1007/s11154-010-9139-z
   PubMed Web of Science ®Google Scholar
• Valassi E, Franz H, Brue T, et al. Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol. 2017;176(5):613–624.10.1530/EJE-16-0967
   PubMed Web of Science ®Google Scholar
• Witek P, Witek J, Zielinski G, et al. Ectopic Cushing’s syndrome in light of modern diagnostic techniques and treatment options. Neuro Endocrinol Lett. 2015;36(3):201–208.
   PubMed Web of Science ®Google Scholar
• Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197–223.10.5306/wjco.v5.i3.197
   PubMedGoogle Scholar
• Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–377.10.1210/jc.2005-1542
   PubMed Web of Science ®Google Scholar
• Cieszynski L, Berendt-Obolonczyk M, Szulc M, et al. Cushing’s syndrome due to ectopic ACTH secretion. Endokrynol Pol. 2016;67(4):458–471.
   PubMed Web of Science ®Google Scholar
• Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion. Cancer. 2011;117(19):4381–4389.10.1002/cncr.26029
   PubMed Web of Science ®Google Scholar
• Ilias I, Torpy DJ, Pacak K, et al. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the national institutes of health. J Clin Endocrinol Metab. 2005;90(8):4955–4962.10.1210/jc.2004-2527
   PubMed Web of Science ®Google Scholar
• Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. A clinicopathologic update. J Thorac Cardiovasc Surg. 1989;98(3):321–332.
   PubMed Web of Science ®Google Scholar
• Sciarra A, Cardi A, Dattilo C, et al. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract. 2006;60(4):462–470.10.1111/ijcp.2006.60.issue-4
   PubMed Web of Science ®Google Scholar
• Kamp K, Alwani RA, Korpershoek E, et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol. 2016;174(3):271–280.10.1530/EJE-15-0968
   PubMed Web of Science ®Google Scholar
• McMahon GT, Blake MA, Wu CL. Case 1-2010. N Engl J Med. 2010;362(2):156–166.10.1056/NEJMcpc0905546
   PubMedGoogle Scholar
• Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol. 2007;51(8):1217–1225.10.1590/S0004-27302007000800007
   PubMedGoogle Scholar
• Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540.10.1210/jc.2008-0125
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and treatment of pituitary adenomas. JAMA. 2017;317(5):516–524.10.1001/jama.2016.19699
   PubMed Web of Science ®Google Scholar
• Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med. 2005;118(12):1340–1346.10.1016/j.amjmed.2005.01.059
   PubMed Web of Science ®Google Scholar
• Zampetti B, Grossrubatscher E, Dalino Ciaramella P, et al. Bilateral inferior petrosal sinus sampling. Endocr Connect. 2016;5(4):R12–R25.10.1530/EC-16-0029
   PubMed Web of Science ®Google Scholar
• Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991;325(13):897–905.10.1056/NEJM199109263251301
   PubMed Web of Science ®Google Scholar
• Santhanam P, Taieb D, Giovanella L, et al. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015;50(2):297–305.10.1007/s12020-015-0689-4
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015;75(8):847–858.10.1007/s40265-015-0397-7
   PubMed Web of Science ®Google Scholar
• Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966–973.10.1093/annonc/mdh216
   PubMed Web of Science ®Google Scholar
• Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. Onco Targets Ther. 2013;6:471–483.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–666.10.1530/ERC-11-0367
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1–2):69–74.10.1016/j.mce.2007.09.006
   PubMed Web of Science ®Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Dev Ther. 2015;9:5075–5086.10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Leo M, Cozzolino A, et al. The treatment of Cushing’s disease. Endocr Rev. 2015;36(4):385–486.10.1210/er.2013-1048
   PubMed Web of Science ®Google Scholar
• van der Pas R, de Herder WW, Hofland LJ, et al. New developments in the medical treatment of Cushing’s syndrome. Endocr Relat Cancer. 2012;19(6):R205–R223.10.1530/ERC-12-0191
   PubMed Web of Science ®Google Scholar
• Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–2462.10.1210/jc.2007-2734
   PubMed Web of Science ®Google Scholar
• Valassi E, Crespo I, Gich I, et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf). 2012;77(5):735–742.10.1111/cen.2012.77.issue-5
   PubMed Web of Science ®Google Scholar
• Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: Is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–1630.10.1210/jc.2013-3628
   PubMed Web of Science ®Google Scholar
• Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100(11):4146–4154.10.1210/jc.2015-2616
   PubMed Web of Science ®Google Scholar
• Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 1991;35(2):169–178.10.1111/j.1365-2265.1991.tb03517.x
   PubMed Web of Science ®Google Scholar
• Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473–481.10.1530/EJE-12-0358
   PubMed Web of Science ®Google Scholar
• Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p′DDD. N Engl J Med. 1979;300(9):459–464.10.1056/NEJM197903013000903
   PubMed Web of Science ®Google Scholar
• Preda VA, Sen J, Karavitaki N, et al. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. Eur J Endocrinol. 2012;167(2):137–143.
   PubMed Web of Science ®Google Scholar
• Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96(9):2796–2804.10.1210/jc.2011-0536
   PubMed Web of Science ®Google Scholar
• Nagy-Mignotte H, Shestaeva O, Vignoud L, et al. Prognostic impact of paraneoplastic Cushing’s syndrome in small-cell lung cancer. J Thorac Oncol. 2014;9(4):497–505.10.1097/JTO.0000000000000116
   PubMed Web of Science ®Google Scholar
• Aniszewski JP, Young WF Jr, Thompson GB, et al. Gushing syndrome doe to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–940.10.1007/s00268-001-0032-5
   PubMed Web of Science ®Google Scholar
• Davi MV, Cosaro E, Piacentini S, et al. Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: a multicenter study. Eur J Endocrinol. 2017;176(4):451–459.10.1530/EJE-16-0809
   PubMed Web of Science ®Google Scholar